Nigeria: Tackling Sickle Cell Anaemia
[This Day] All critical stakeholders should work towards curtailing the disease (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - June 19, 2023 Category: African Health Tags: Health and Medicine Nigeria West Africa Source Type: news

2023 Health Care Heroes: M Health Fairview's Dr. Alex Boucher raises awareness around genetic blood disorder
Dr. Alex Boucher, assistant professor of hematology, pediatrics and medicine at the U of M and M Health Fairview, is improving the lives of people with sickle cell disease, one patient at a time. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 15, 2023 Category: Biotechnology Authors: Mollee Francisco Source Type: news

CRISPR Therapy Exceeds Targets in Thalassemia, Sickle Cell Disease
(MedPage Today) -- Data from two pivotal trials suggest that a single infusion of the CRISPR-based gene therapy exagamglogene autotemcel (exa-cel) can provide a "functional cure" for patients with transfusion-dependent beta-thalassemia or severe... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 13, 2023 Category: Hematology Source Type: news

Message from Dr Ahmed Al-Mandhari, WHO Regional Director, on the occasion of World Blood Donor ...
Every year on 14 June, countries around the world celebrate World Blood Donor Day. This year’s campaign focuses on patients requiring life-long support with blood transfusion or plasma proteins. The campaign highlights the role that every single person can play, by giving the valuable gift of blood or plasma regularly to ensure a safe and sustainable supply of blood and blood products for all those in need. Access to a secure blood supply based on voluntary unpaid donation is vital for all patients, including many requiring life-long and regular transfusions for conditions such as sickle-cell anaemia and thalassaemia. I...
Source: WHO EMRO News - June 13, 2023 Category: Middle East Health Source Type: news

More Evidence Gene Therapy Might Cure Sickle Cell Disease
MONDAY, June 12, 2023 -- A clinical trial that ’s attempting to discover a cure for sickle cell disease has found a new gene therapy to be safe and successful in four patients. Two of the patients were treated at Cleveland Clinic Children’s in... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 12, 2023 Category: General Medicine Source Type: news

Kenya sickle cell: Fighting to dispel the myths around the disease
Kenyan Lea Kilenga Bey campaigns for better treatment for those who have the genetic disease. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - June 12, 2023 Category: Consumer Health News Source Type: news

Editas' sickle cell CRISPR therapy shows early promise, but can it stand out against Vertex?
Editas Medicine has shared#editasmedicine (Source: Reuters: Health)
Source: Reuters: Health - June 10, 2023 Category: Consumer Health News Source Type: news

The FDA Could Approve The First CRISPR Drug Is Just 6 Months
Shares of Crispr Therapeutics (CRSP) dipped Friday after the Food and Drug Administration indicated it could approve the company's gene-edited sickle cell treatment as early as December. CRSP stock had been up more than 7% in premarket action before falling. Crispr's drug is called exa-cel. It…#crisprtherapeutics #crsp #fda #bullishly #rbccapitalmarkets #brianabrahams #vertex #crispr #abrahams #stockexactsciences (Source: Reuters: Health)
Source: Reuters: Health - June 9, 2023 Category: Consumer Health News Source Type: news

New data show Roche ’s subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH)
The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with comparable safety, in people new to C5 inhibitors1Monthly self-administration of subcutaneous crovalimab has the potential to address the high burden of a disease that requires lifelong treatment including in settings where access to currentC5 inhibitors is limited1,2The COMMODORE 1 study in people switching from currently approved C5 inhibitors supported the consistent benefit-risk profile of crovalimab as seen in the COMMODORE 2 study3Basel, 09 June 2023 - Roche (SIX: RO, ROG; ...
Source: Roche Investor Update - June 9, 2023 Category: Pharmaceuticals Source Type: news

New data show Roche ’s subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH)
The COMMODORE 2 study demonstrated that subcutaneous crovalimab every four weeks was non-inferior to intravenous eculizumab every two weeks, with comparable safety, in people new to C5 inhibitors1Monthly self-administration of subcutaneous crovalimab has the potential to address the high burden of a disease that requires lifelong treatment including in settings where access to currentC5 inhibitors is limited1,2The COMMODORE 1 study in people switching from currently approved C5 inhibitors supported the consistent benefit-risk profile of crovalimab as seen in the COMMODORE 2 study3Basel, 09 June 2023 - Roche (SIX: RO, ROG; ...
Source: Roche Media News - June 9, 2023 Category: Pharmaceuticals Source Type: news

Tallying the cost-effectiveness of an equity-enhancing sickle cell therapy
A new Yale study of an equity-enhancing gene therapy for sickle cell disease showed that cost effectiveness is not just about cheaper therapies. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 7, 2023 Category: Universities & Medical Training Source Type: news

Ted Love, now the chair of biotech's big trade group, talks drug access, leadership and 'crazy' co-pays
Love was CEO of sickle cell disease drug maker Global Blood Therapeutics in San Francisco before its acquisition last year by Pfizer. He begins his two-year stint as chair of BIO's board at a critical time for the life sciences industry. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 7, 2023 Category: Biotechnology Authors: Ron Leuty Source Type: news

Ted Love, now the chair of biotech's big trade group, talks drug access, leadership and 'crazy' co-pays
Love was CEO of sickle cell disease drug maker Global Blood Therapeutics in South San Francisco before its acquisition last year by Pfizer. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - June 7, 2023 Category: Health Management Authors: Ron Leuty Source Type: news

Sickle Cell Disease Poses Major Risk for Pregnant Black Patients
(MedPage Today) -- Sickle cell disease (SCD) was associated with four-fold increased risk of severe maternal morbidity (SMM), according to a large cohort study. The condition accounted for 8.9% of disparities in SMM between Black and white patients... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 5, 2023 Category: American Health Source Type: news

Gene Therapy Not Cost-Effective for Sickle Cell by Conventional Measures
MONDAY, June 5, 2023 -- For persons with sickle cell disease (SCD), gene therapy seems not to be cost-effective per conventional cost-effectiveness analysis (CEA) standards and can be equitable per distributional CEA (DCEA) standards, which... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 5, 2023 Category: Pharmaceuticals Source Type: news